Rheumatology Network's Top 5: June 4, 2022


Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2022.

Massimo Radin, MD, PhD: TuTOR App Tailors Oral Therapy in Rheumatoid Arthritis:

Massimo Radin, MD, PhD, explains how tailoring oral therapy in rheumatoid arthritis, via the TuTOR App, can improve medication adherence.

John K Botson, MD, RPh, CCD: Pegloticase Combination Therapy for Uncontrolled Gout

John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.

Deucravacitinib Meets Primary, Secondary Endpoints for Treatment of SLE

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment

Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.

Nicola Luigi Bragazzi, MD, PhD: Sex-Based Medicine in Psoriatic Arthritis

Nicola Luigi Bragazzi, MD, PhD, explains the importance of sex-based medicine in psoriatic arthritis and shares his advice for future studies.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.